The Yale Epilepsy Program is participating in a clinical trial of responsive electrical stimulation of the brain as a treatment for intractable partial epilepsy using an implanted medical device. NeuroPace, Inc. is sponsoring this investigational device study of their Responsive Neurostimulator (RNS™) system. The NeuroPace RNS™ is designed to detect abnormal electrical activity in the brain and to deliver small amounts of electrical stimulation to suppress seizures before there are any seizure symptoms. The study is open to patients 18 years of age or older with partial onset seizures that are resistant or hard to treat using two or more antiepileptic medications. Candidates will continue to receive their epilepsy medications while participating in the trial.
For further information, contact Robert B. Duckrow, M.D.